Ionis Pharmaceuticals (IONS) Reports Strong 1Q, Eplontersen PN Data Soon - BMO Capital

May 6, 2022 6:54 AM EDT
Get Alerts IONS Hot Sheet
Price: $38.06 +2.81%

Rating Summary:
    9 Buy, 8 Hold, 4 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 1 | Down: 1 | New: 0
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

BMO Capital analyst Do Kim reiterated an Outperform rating and $70.00 price target on Ionis Pharmaceuticals (NASDAQ: IONS) after the company reported 1Q revenue / non-GAAP EPS of $142mm / $(0.27) which beat
cons. $123mm / $(0.48).

The analyst stated "Strong 1Q driven by $40mm BIIB milestones for neuro programs and higher licensing revenue, while Spinraza performed well and opex was lower. Guidance reaffirmed and seems very achievable. Key focus on Eplontersen with ATTR-PN data midyear, and IONS explained rationale for extending CM study (partner AZN) to increase patients/duration that will provide even more robust data and potentially position drug better in large/competitive market."

For an analyst ratings summary and ratings history on Ionis Pharmaceuticals click here. For more ratings news on Ionis Pharmaceuticals click here.

Shares of Ionis Pharmaceuticals closed at $38.05 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View

Related Entities

BMO Capital